NV-AIRCRAFT-PERFORMANCE
11.10.2021 22:31:10 CEST | Business Wire | Press release
NBAA-BACE – Aircraft Performance Group (APG) announces iPreFlight Genesis™ Pro, a new solution that seamlessly coordinates between aircraft dispatchers and flight crews, enabling optimized global flight planning with integrated enroute, take-off, and landing performance. iPreFlight Genesis Pro is the culmination of APG’s proven track record of 20+ years of providing trusted runway performance for over 350 aircraft profiles and over 9,000 monitored airports combined with RocketRoute’s global routing and filing capabilities and Seattle Avionics’ global ChartData. APG, RocketRoute, and Seattle Avionics all recently joined forces under the AFV Partners LLC umbrella.
iPreFlight Genesis Pro provides optimized and fully integrated tools for both dispatchers and flight crews. Dispatchers have access to a comprehensive and flexible web-based application for global routing, runway performance, weight and balance, and flight plan calculation and filing. Flight crews can use the iPad application to review and modify trip plans at any point during the mission, verify runway performance calculations, and check weight and balance parameters. Routes and flight plans are fully synchronized between the web and iPad applications enabling seamless bi-directional collaboration between pilots and dispatchers, eliminating inefficient phone calls, significantly decreasing operational change reaction times, and improving communication accuracy.
“Flight preparation boils down to one important question: What is the most safe, compliant, efficient, and timely manner to get to my destination based on optimized routing considering my aircraft's performance capabilities?” said Shawn Mechelke, president of the Aviation Group at AFV Partners. “APG’s runway performance system is the industry leader in business aviation. Now, with global route optimization and flight plan filing from RocketRoute and global charts from Seattle Avionics, iPreFlight Genesis Pro brings together the many data, calculations, and performance considerations into a seamless interface that is powerful, easy to use, and integrated in both mobile and web applications – no matter where in the world a mission takes you.”
“iPreFlight Genesis Pro uniquely combines the assets and IP of all three companies within our Aviation Group to optimize the flight route based on multiple parameters such as type of aircraft, load factor, weather conditions, and many more data points to deliver a high return on investment solution with a meaningful sustainability impact due to an optimized fuel burn profile for our customers,” said Tony Aquila, founder, chairman, and CEO of AFV Partners. “This solution is the first of many that will leverage the people, technology, and data across APG, RocketRoute, and Seattle Avionics to create new products that will have a lasting positive impact on aviation and the environment.”
KEY BENEFITS
- Realtime responsiveness delivers a superior experience to clients
- Simplifies dispatcher and crew workflow
- Lowers training costs
- Reduces unplanned downtime
- Lowers operating costs and total cost of ownership
KEY FEATURES
- Bi-directional synchronization between dispatchers and flight crews
- Integrated runway performance with flight planning
- Global routing and filing
- Weight and Balance
- Global charts for in-flight and pre-flight use
- Supports web platforms and mobile devices
- Application Programming Interfaces (APIs) allow connection to customer applications
About Aircraft Performance Group
Aircraft Performance Group (APG) is a leading global provider of proprietary flight operations software solutions into the aftermarket of the aerospace industry. APG operates a SaaS business model focused on the corporate and business aviation segment of the aerospace industry. www.flyapg.com
About RocketRoute
RocketRoute is a leading software platform simplifying route planning and flight plan submissions to air traffic controllers. RocketRoute solutions span private, business and commercial aviation, and are the backbone to many air rescue operations in Europe. www.rocketroute.com
About Seattle Avionics
Seattle Avionics creates compelling pre-flight and in-flight user experiences with its cloud-based solutions providing direct user access to flight planning, weather, fuel prices and group document management for the general aviation market. Their ChartData brand of global FAA-certified and georeferenced charts and data is proven and used in leading in-panel avionics systems around the world. www.seattleavionics.com
About AFV Partners
Founded by serial technology entrepreneur and investor Tony Aquila and anchored by some of the world’s largest and most experienced investors, AFV Partners is a long-term sustainable capital vehicle that invests globally in mission critical software, data and disruptive marketplaces that contribute to a net positive impact on the environment. AFV Partners is headquartered in Argyle, TX with offices in Jackson Hole, WY and Zurich, Switzerland. www.afvpartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005683/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
